Bibliothèque

Conversion therapy for stage IV gastric cancer.

Thérapies de Conversion

Hu, C., Terashima, M., & Cheng, X. (2023). Conversion therapy for stage IV gastric cancer.. Sci Bull (Beijing), 68(7), 653-656. https://doi.org/10.1016/j.scib.2023.03.011

15/04/2023 Lire →

Apatinib combined with SOX regimen for conversion therapy in advanced gastric cancer patients: a retrospective cohort study.

BACKGROUND: Recently, many studies have shown that the progress of conversion therapy can provide surgical opportunities for patients with advanced gastric cancer (GC) and bring survival benefits. How…

Thérapies de Conversion

Deng, Y. Y., Jiang, D. Y., Zhu, P. F., Lu, H., Liu, Q., Zhang, X., Pan, S. Y., Chen, Z. L., & Yang, L. (2023). Apatinib combined with SOX regimen for conversion therapy in advanced gastric cancer patients: a retrospective cohort study.. World J Surg Oncol, 21(1), 129. https://doi.org/10.1186/s12957-023-02973-3

11/04/2023 Lire →

Management of locally advanced intrahepatic cholangiocarcinoma: a narrative review.

BACKGROUND AND OBJECTIVE: Intrahepatic cholangiocarcinoma (ICC) is an aggressive primary hepatic malignancy, which has increased in incidence over the past decades. While surgical resection is the sta…

Thérapies de Conversion

Bressler, L., Bath, N., Manne, A., Miller, E., & Cloyd, J. M. (2023). Management of locally advanced intrahepatic cholangiocarcinoma: a narrative review.. Chin Clin Oncol, 12(2), 15. https://doi.org/10.21037/cco-22-115

01/04/2023 Lire →

Treatment Strategy for Intermediate-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization, Systemic Therapy, and Conversion Therapy.

Transarterial chemoembolization (TACE) has been standard treatment for intermediate-stage hepatocellular carcinoma (HCC). However, all intermediate-stage HCC patients did not benefit from TACE treatme…

Thérapies de Conversion

Hatanaka, T., Yata, Y., Naganuma, A., & Kakizaki, S. (2023). Treatment Strategy for Intermediate-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization, Systemic Therapy, and Conversion Therapy.. Cancers (Basel), 15(6). https://doi.org/10.3390/cancers15061798

16/03/2023 Lire →

An exploratory human study of superstable homogeneous lipiodol-indocyanine green formulation for precise surgical navigation in liver cancer.

The clinical applications of transcatheter arterial embolization (TAE) conversion therapy combined with hepatectomy have been severely restricted by ill-defined tumoral boundaries and miniscule hidden…

Thérapies de Conversion

He, P., Xiong, Y., Luo, B., Liu, J., Zhang, Y., Xiong, Y., Su, S., Fang, C., Peng, Y., Cheng, H., Chu, C., Mao, J., Li, J., Li, B., Yin, Z., Tian, J., & Liu, G. (2023). An exploratory human study of superstable homogeneous lipiodol-indocyanine green formulation for precise surgical navigation in liver cancer.. Bioeng Transl Med, 8(2), e10404. https://doi.org/10.1002/btm2.10404

01/03/2023 Lire →

Anti-PD-1 plus anti-angiogenesis combined with chemotherapy in patients with HER2-negative advanced or metastatic gastric cancer: a multi-institutional retrospective study.

BACKGROUND: Immunotherapy plus chemotherapy have been confirmed to be effective in treating advanced or metastatic gastric cancer (GC). Anti- programmed death-1 (PD-1) plus antiangiogenic agents have …

Thérapies de Conversion

Xu, T., Wang, W., Bao, R., Xia, X., Zhang, J., Huang, M., Chen, X., Wang, R., Zhang, H., Liu, X., Li, Q., & Shu, Y. (2023). Anti-PD-1 plus anti-angiogenesis combined with chemotherapy in patients with HER2-negative advanced or metastatic gastric cancer: a multi-institutional retrospective study.. J Gastrointest Oncol, 14(1), 175-186. https://doi.org/10.21037/jgo-23-73

28/02/2023 Lire →

Banning conversion therapy for trans people.

Thérapies de Conversion

Motmans, J., Cannoot, P., & T'Sjoen, G. (2023). Banning conversion therapy for trans people.. BMJ, 380, 341. https://doi.org/10.1136/bmj.p341

22/02/2023 Lire →

Current Status of Lymphangiogenesis: Molecular Mechanism, Immune Tolerance, and Application Prospect.

The lymphatic system is a channel for fluid transport and cell migration, but it has always been controversial in promoting and suppressing cancer. VEGFC/VEGFR3 signaling has long been recognized as a…

Thérapies de Conversion

Deng, H., Zhang, J., Wu, F., Wei, F., Han, W., Xu, X., & Zhang, Y. (2023). Current Status of Lymphangiogenesis: Molecular Mechanism, Immune Tolerance, and Application Prospect.. Cancers (Basel), 15(4). https://doi.org/10.3390/cancers15041169

11/02/2023 Lire →

Conversion therapy in liver transplantation for hepatocellular carcinoma: What's new in the era of molecular and immune therapy?

BACKGROUND: Hepatocellular carcinoma (HCC) is the sixth most common cancer globally, with limited therapies and unsatisfactory prognosis once in the advanced stages. With promising advances in locoreg…

Thérapies de Conversion

Jiang, C., Sun, X. D., Qiu, W., Chen, Y. G., Sun, D. W., & Lv, G. Y. (2023). Conversion therapy in liver transplantation for hepatocellular carcinoma: What's new in the era of molecular and immune therapy?. Hepatobiliary Pancreat Dis Int, 22(1), 7-13. https://doi.org/10.1016/j.hbpd.2022.10.006

01/02/2023 Lire →

Conversion therapy with immunotherapy plus chemotherapy achieves a pathological complete response in stage IIIC NSCLC.

As stage IIIC non-small cell lung cancer (NSCLC) is not recommended for surgical resection, the survival and prognosis for stage IIIC NSCLC remain poor. More powerful and individualized therapies are …

Thérapies de Conversion

Fu, Y., Duan, W., Xu, R., & Chen, J. (2023). Conversion therapy with immunotherapy plus chemotherapy achieves a pathological complete response in stage IIIC NSCLC.. Front Immunol, 14, 1268153. https://doi.org/10.3389/fimmu.2023.1268153

01/01/2023 Lire →

Study protocol of a phase II clinical trial evaluating the efficacy of neoadjuvant intraperitoneal and systemic albumin-bound paclitaxel combined with camrelizumab and S-1 in the treatment of patients with exfoliative cell-positive gastric cancer.

BACKGROUND: Currently, gastric cancer with positive lavage cytology without gross peritoneal dissemination (GC-CY1) is a special type of metastatic form with poor prognosis. Consensus guidelines on tr…

Thérapies de Conversion

Lv, J., Wu, J., Wu, H., Ding, P., Guo, H., Yang, P., Tian, Y., Liu, Y., & Zhao, Q. (2023). Study protocol of a phase II clinical trial evaluating the efficacy of neoadjuvant intraperitoneal and systemic albumin-bound paclitaxel combined with camrelizumab and S-1 in the treatment of patients with exfoliative cell-positive gastric cancer.. Front Oncol, 13, 1201928. https://doi.org/10.3389/fonc.2023.1201928

01/01/2023 Lire →

A Retrospective Analysis of Conversion Therapy with Lenvatinib, Sintilimab, and Arterially-Directed Therapy in Patients with Initially Unresectable Hepatocellular Carcinoma.

PURPOSE: The purpose of this study was to investigate the triple-combination therapy of lenvatinib plus sintilimab plus arterially-directed therapy as a conversion therapy for initially unresectable h…

Thérapies de Conversion

Gan, L., Lang, M., Tian, X., Ren, S., Li, G., Liu, Y., Han, R., Zhu, K., Li, H., Wu, Q., Cui, Y., Zhang, W., Fang, F., Li, Q., & Song, T. (2023). A Retrospective Analysis of Conversion Therapy with Lenvatinib, Sintilimab, and Arterially-Directed Therapy in Patients with Initially Unresectable Hepatocellular Carcinoma.. J Hepatocell Carcinoma, 10, 673-686. https://doi.org/10.2147/JHC.S404675

01/01/2023 Lire →